PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+4.69%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$4.12B
AUM Growth
+$4.12B
(+12%)
Cap. Flow
+$490M
Cap. Flow
% of AUM
11.9%
Top 10 Holdings %
Top 10 Hldgs %
35.31%
Holding
108
New
19
Increased
30
Reduced
27
Closed
22
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$203M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$178M |
| 3 |
Gilead Sciences
GILD
|
$92.2M |
| 4 |
Sarepta Therapeutics
SRPT
|
$83.1M |
| 5 |
Alibaba
BABA
|
$65.9M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$95.3M |
| 2 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$83.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$77.2M |
| 4 |
Pfizer
PFE
|
$52M |
| 5 |
Elevance Health
ELV
|
$44.4M |
Sector Composition
| 1 | Healthcare | 70.69% |
| 2 | Technology | 11.2% |
| 3 | Communication Services | 5.11% |
| 4 | Consumer Discretionary | 4.12% |
| 5 | Financials | 2.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $299M | 5.68% | 1,785,597 +1,210,760 | +211% | +$203M |
|
|
2
BioMarin Pharmaceuticals
BMRN
$11.2B
| $178M | 3.38% | +2,079,388 | New | +$178M |
|
3
Humana
HUM
$36.5B
| $149M | 2.83% | 562,177 +197,704 | +54% | +$52.5M |
|
4
Zimmer Biomet
ZBH
$21B
| $137M | 2.61% | 1,165,494 +214,248 | +23% | +$25.2M |
|
|
WCG
5
DELISTED
Wellcare Health Plans, Inc.
WCG
| $137M | 2.6% | 480,244 +147,410 | +44% | +$42M |
|
6
Penumbra
PEN
$10.6B
| $123M | 2.35% | 771,799 +44,742 | +6% | +$7.16M |
|
|
BOLD
7
DELISTED
Audentes Therapeutics, Inc
BOLD
| $122M | 2.32% | 3,228,679 +1,198,198 | +59% | +$45.4M |
|
|
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $107M | 2.04% | 1,828,378 -1,426,852 | -44% | -$83.7M |
|
9
IQVIA
IQV
$32.4B
| $103M | 1.95% | 638,326 +361,517 | +131% | +$58.2M |
|
10
ICU Medical
ICUI
$3.15B
| $97.4M | 1.85% | 386,592 +11,732 | +3% | +$2.96M |
|
|
11
Alibaba
BABA
$322B
| $96.8M | 1.84% | 571,376 +389,164 | +214% | +$65.9M |
|
|
12
Gilead Sciences
GILD
$140B
| $92.2M | 1.75% | +1,364,288 | New | +$92.2M |
|
13
Salesforce
CRM
$245B
| $90.9M | 1.73% | 598,759 +393,361 | +192% | +$59.7M |
|
|
MYOK
14
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $89.1M | 1.69% | 1,777,409 +176,102 | +11% | +$8.83M |
|
15
Stryker
SYK
$150B
| $88.2M | 1.67% | 428,849 -150,595 | -26% | -$31M |
|
16
HCA Healthcare
HCA
$94.5B
| $85.1M | 1.62% | 629,767 +342,816 | +119% | +$46.3M |
|
17
Edwards Lifesciences
EW
$47.8B
| $84.3M | 1.6% | 456,359 +96,052 | +27% | +$17.7M |
|
|
18
Sarepta Therapeutics
SRPT
$1.78B
| $83.1M | 1.58% | +546,786 | New | +$83.1M |
|
19
Molina Healthcare
MOH
$9.8B
| $77.4M | 1.47% | 540,898 +40,360 | +8% | +$5.78M |
|
20
Esperion Therapeutics
ESPR
$448M
| $72.3M | 1.37% | 1,555,112 -71,967 | -4% | -$3.35M |
|
|
21
Pfizer
PFE
$141B
| $70.7M | 1.34% | 1,632,685 -1,200,411 | -42% | -$52M |
|
22
Microchip Technology
MCHP
$35.1B
| $65.3M | 1.24% | 753,529 -273,292 | -27% | -$23.7M |
|
23
DexCom
DXCM
$29.5B
| $61.7M | 1.17% | +411,696 | New | +$61.7M |
|
24
PayPal
PYPL
$67.1B
| $59.8M | 1.14% | 522,446 +14,847 | +3% | +$1.7M |
|
25
Voyager Therapeutics
VYGR
$186M
| $57.6M | 1.09% | 2,117,388 +166,327 | +9% | +$4.53M |
|